Tammy Utset to Treatment Outcome
This is a "connection" page, showing publications Tammy Utset has written about Treatment Outcome.
Connection Strength
0.094
-
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024 Mar; 6(3):e168-e177.
Score: 0.025
-
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002 Sep; 29(9):1907-13.
Score: 0.022
-
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ß Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2018 09; 70(9):1470-1480.
Score: 0.017
-
Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012 Aug; 42(1):56-65.
Score: 0.011
-
Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):865-74.
Score: 0.010
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
Score: 0.009